Mouse anti-CIP2A Monoclonal Antibody Affinity Purified [2A1-9A4]
Product Details
Specifications
Request Formulation Change Tris-buffered Saline containing 0.09% Sodium Azide, BSA-Free
Request Formulation Change
The hybridoma was grown in a bioreactor and the antibody was purified using a mouse immunoglobulin binding ligand.
Additional Product Information
CIP2A (cancerous inhibitor of PP2A) was originally identified as p90, a cytoplasmic autoantigen found in the serum from a cancer patient. It was later described as a protein that interacted with the c-myc oncogene and functioned as an inhibitor of protein phosphatase 2A (PP2A) activity. Inhibition of PP2A phosphatase activity by CIP2A prevents c-myc phosphorylation and counteracts c-myc proteolytic degradation, thereby stabilizing c-myc and promoting cell growth and transformation. CIP2A is found to be overexpressed in some human malignancies and is thus classified as an oncogene that may be an important contributor to tumor formation.
Alternate Names
cancerous inhibitor of PP2A; cancerous inhibitor of protein phosphatase 2A; KIAA1524; p90; p90 autoantigen; protein CIP2A
Applications
All western blot analysis is performed using 5% Milk-TBST for blocking and as antibody diluent. Primary antibody is incubated overnight.
Western blots are performed using Goat anti-Mouse IgG Heavy and Light Chain Antibody (Cat. No. A90-216P).